CVA Family Office LLC Purchases 74 Shares of Zoetis Inc. $ZTS

CVA Family Office LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 6.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,173 shares of the company’s stock after purchasing an additional 74 shares during the period. CVA Family Office LLC’s holdings in Zoetis were worth $183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of ZTS. Nova Wealth Management Inc. purchased a new position in Zoetis during the 1st quarter valued at $25,000. 1248 Management LLC purchased a new stake in shares of Zoetis during the first quarter valued at $27,000. Saudi Central Bank bought a new position in shares of Zoetis in the first quarter worth about $29,000. Cornerstone Planning Group LLC increased its stake in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after buying an additional 88 shares during the period. Finally, REAP Financial Group LLC lifted its holdings in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.2%

Zoetis stock opened at $146.14 on Friday. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $184.40. The business has a fifty day moving average of $148.18 and a two-hundred day moving average of $153.57. The firm has a market cap of $64.77 billion, a P/E ratio of 25.15, a P/E/G ratio of 2.35 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the prior year, the business posted $1.56 EPS. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis’s payout ratio is presently 34.42%.

Analyst Ratings Changes

ZTS has been the topic of a number of research analyst reports. UBS Group dropped their target price on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research note on Monday, October 20th. Argus reissued a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Friday. Finally, Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Zoetis presently has an average rating of “Hold” and an average target price of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.